CELLUMED CO.,LTD. Cellumed Co.,Ltd. Share Price
Equities
A049180
KR7049180003
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,448 KRW | -8.06% |
|
-20.40% | -32.65% |
| 05-16 | Cellumed Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 03-21 | Cellumed Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 122B 88.02M 6.96B | Sales 2023 | 95.55B 68.89M 5.44B | Capitalization | 92.01B 66.34M 5.24B |
|---|---|---|---|---|---|
| Net income 2022 | -5.57B -4.02M -317M | Net income 2023 | -37.3B -26.89M -2.12B | EV / Sales 2022 | 1.49 x |
| Net Debt 2022 | 184M 133K 10.51M | Net Debt 2023 | 8.84B 6.37M 504M | EV / Sales 2023 | 1.06 x |
| P/E ratio 2022 |
-31.5
x | P/E ratio 2023 |
-2.45
x | Employees | 103 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 81.18% |
More Fundamentals
* Assessed data
More news
| 1 day | -8.06% | ||
| 1 week | -20.40% | ||
| Current month | -5.11% | ||
| 1 month | -12.82% | ||
| 3 months | -24.74% | ||
| 6 months | -33.27% | ||
| Current year | -32.65% |
1 week
1 440.00
1 738.00
1 month
1 402.002 045.00
Current year
1 402.002 870.00
1 year
1 402.005 300.00
3 years
1 402.0013 750.00
5 years
1 402.0013 750.00
10 years
1 402.0039 700.00
| Managers | Title | Age | Since |
|---|---|---|---|
In-Soo Yoo
CEO | Chief Executive Officer | 62 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
In-Soo Yoo
CEO | Chief Executive Officer | 62 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/06/24 | 1,448 | -8.06% | 631,633 |
| 20/06/24 | 1,575 | +0.13% | 1,270,825 |
| 19/06/24 | 1,573 | -1.69% | 663,528 |
| 18/06/24 | 1,600 | -8.36% | 886,609 |
| 17/06/24 | 1,746 | -4.01% | 1,833,920 |
End-of-day quote Korea S.E., June 20, 2024
More quotes
CELLUMED CO., LTD., formerly Korea Bone Bank CO., LTD, is a Korea-based company engaged in the manufacture and sale of medical equipment and biosimilars. The Companyâs products consist of allografts for tissue repair; bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration; biosimilars, such as bone morphogenetic protein 2 (BMP2) reagents and others, as well as medical devices, such as spinal fixation systems, joint replacements and navigation systems. The Company sells its products within domestic market and to overseas markets.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -32.65% | 51.28M | |
| +14.42% | 131B | |
| -7.43% | 11.06B | |
| -15.80% | 7.33B | |
| +42.18% | 5.69B | |
| -20.14% | 4.83B | |
| +8.58% | 3.45B | |
| -19.51% | 2.47B | |
| -17.70% | 1.93B | |
| -19.46% | 1.79B |
- Stock Market
- Equities
- A049180 Stock
